Actualités et vidéos - PULMATRIX INC.

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update PR Newswire BEDFORD, Mass., March 28, 2024 2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3 rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and...

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives PR Newswire BEDFORD, Mass., Jan. 8, 2024 Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix Pulmatrix to significantly reduce cash burn and focus on...

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire BEDFORD, Mass., Nov. 9, 2023 Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline data anticipated in H2 2024 Received "study may proceed" letter on an IND for a Phase 2 study of PUR3100 for acute migraine $21.3 million in cash and cash equivalents at the end of Q3 2023...

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine PR Newswire BEDFORD, Mass., Sept. 19, 2023 Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine BEDFORD, Mass. , Sept. 19, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative...

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole PR Newswire BEDFORD, Mass., Aug. 23, 2023 Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazole Pulmatrix is currently enrolling patients in a Phase 2 study of PUR1900 in adults with ABPA and Asthma BEDFORD, Mass. , Aug....

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire BEDFORD, Mass., Aug. 10, 2023 Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and topline data anticipated in Q3 2024 Submitted an IND for a Phase 2 study of PUR3100 for Acute Migraine $25.8 million in cash and cash equivalents at the end of Q2 2023 providing projected cash runway...

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine PR Newswire LEXINGTON, Mass., July 11, 2023 LEXINGTON, Mass. , July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease, today announced the submission of an investigational...

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society PR Newswire LEXINGTON, Mass., June 15, 2023 LEXINGTON, Mass. , June 15, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced it will present data at the American Headache Society 65 th Annual...

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention PR Newswire LEXINGTON, Mass., May 24, 2023 Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine LEXINGTON, Mass. , May 24, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire LEXINGTON, Mass., May 12, 2023 Patient dosing initiated for Phase 2b study of PUR1900 for ABPA Phase 1 study of PUR3100 for migraine achieves positive topline results $30.8 million in cash and cash equivalents at the end of Q1 2023 providing projected cash runway into Q4 2024 LEXINGTON, Mass. , May 12, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company...

Pulmatrix Supports World Asthma Day 2023 PR Newswire LEXINGTON, Mass., May 2, 2023 LEXINGTON, Mass. , May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system disease using its patented iSPERSE™ technology, today announced its support for World Asthma Day. Margaret Wasilewski , M.D., Chief Medical Officer of Pulmatrix, commented, "World Asthma Day is an...

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update PR Newswire LEXINGTON, Mass., March 30, 2023 PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at the end of 2022 providing cash runway into Q2 2024 LEXINGTON, Mass. , March 30, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company...

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma PR Newswire LEXINGTON, Mass., Feb. 6, 2023 LEXINGTON, Mass. , Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. ( NASDAQ : PULM ), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE ™ technology, today announced the first patient dosed in a Phase 2b trial...

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" PR Newswire LEXINGTON, Mass., Jan. 25, 2023 LEXINGTON, Mass. , Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced it will host a virtual key opinion leader (KOL) event, "PUR3100 for the...

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology PR Newswire LEXINGTON, Mass., Jan. 23, 2023 LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the acceptance of an abstract for presentation at the American Academy of Allergy, Asthma...

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine PR Newswire LEXINGTON, Mass., Jan. 4, 2023 PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minute T max and C max within the targeted therapeutic range for all three doses tested LEXINGTON, Mass. , Jan. 4, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical...

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire LEXINGTON, Mass., Nov. 10, 2022 PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash and cash equivalents at end of Q3 2022 LEXINGTON, Mass. , Nov. 10, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address...

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine PR Newswire LEXINGTON, Mass., Sept. 26, 2022 Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects pharmacokinetic data from the Phase 1 study in Q4 2022 LEXINGTON, Mass. , Sept. 26, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative...

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire LEXINGTON, Mass., Aug. 8, 2022 Pulmazole is on track for Phase 2b study start in Q1 2023 PUR3100 Phase 1 study is underway with data anticipated in Q4 2022 Ends Q2 with $42.9 million in cash and cash equivalents LEXINGTON, Mass. , Aug. 8, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious...

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine New inhaled formulation of dihydroergotamine (DHE) intended for acute migraine therapy begins clinical development with Phase 1 study PR Newswire LEXINGTON, Mass., July 12, 2022 LEXINGTON, Mass. , July 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology,...